S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:ADMS

Adamas Pharmaceuticals Stock Forecast, Price & News

$4.74
+0.04 (+0.85 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.38
Now: $4.74
$4.80
50-Day Range
$4.46
MA: $5.40
$6.79
52-Week Range
$1.90
Now: $4.74
$9.15
Volume550,135 shs
Average Volume910,178 shs
Market Capitalization$144.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.96
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Adamas Pharmaceuticals logo

Headlines

Adamas Pharmaceuticals: Q4 Earnings Insights
February 24, 2021 |  finance.yahoo.com
Adamas Pharmaceuticals, Inc. to Host Earnings Call
February 23, 2021 |  finance.yahoo.com
A Preview Of Adamas Pharmaceuticals's Earnings
February 22, 2021 |  benzinga.com
Biotech Stocks Awaiting FDA Decision In February
January 25, 2021 |  nasdaq.com
Adamas to Present at Upcoming ICR Conference
January 7, 2021 |  finance.yahoo.com
Adamas Completes Acquisition of OSMOLEX ER®
January 5, 2021 |  finance.yahoo.com
Adamas to Present at Upcoming H.C. Wainwright Conference
January 4, 2021 |  finance.yahoo.com
Is ADMS A Good Stock To Buy Now?
December 12, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500
Employees136
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.64 million
Book Value($0.03) per share

Profitability

Net Income$-105,190,000.00

Miscellaneous

Market Cap$144.89 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

493rd out of 1,972 stocks

Pharmaceutical Preparations Industry

240th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$4.74
+0.04 (+0.85 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

Is Adamas Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Adamas Pharmaceuticals stock.
View analyst ratings for Adamas Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Adamas Pharmaceuticals?

Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adamas Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 923,500 shares, a decrease of 47.8% from the January 28th total of 1,770,000 shares. Based on an average trading volume of 528,500 shares, the short-interest ratio is presently 1.7 days. Currently, 4.0% of the company's stock are short sold.
View Adamas Pharmaceuticals' Short Interest
.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Adamas Pharmaceuticals
.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) posted its quarterly earnings results on Monday, February, 22nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.11.
View Adamas Pharmaceuticals' earnings history
.

How has Adamas Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMS stock has increased by 55.4% and is now trading at $4.74.
View which stocks have been most impacted by COVID-19
.

What guidance has Adamas Pharmaceuticals issued on next quarter's earnings?

Adamas Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.2-74.2 million, compared to the consensus revenue estimate of $75.15 million.

What price target have analysts set for ADMS?

4 brokers have issued 1 year price objectives for Adamas Pharmaceuticals' shares. Their forecasts range from $12.00 to $12.50. On average, they expect Adamas Pharmaceuticals' stock price to reach $12.25 in the next twelve months. This suggests a possible upside of 158.4% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:
  • Mr. Neil F. McFarlane, CEO & Director (Age 48, Pay $784.85k)
  • Mr. Christopher B. Prentiss, Chief Financial Officer (Age 46, Pay $549.47k)
  • Mr. Vijay Shreedhar Ph.D., Chief Commercial Officer (Age 50, Pay $685.89k)
  • Ms. Sarah Mathieson, Head of Corp. Communications, Patient Advocacy & Engagement
  • Mr. Dean Hart, Sr. VP of Sales
  • Dr. Jill M. Jene, Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management (Age 48)
  • Mr. Eric C. Schlezinger, Head of HR (Age 54)
  • Ms. Melissa Masterson, Sr. VP of Commercial Operations & Market Access
  • Mr. Adrian Quartel M.D., Chief Medical Officer

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Adamas Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (3.88%), Renaissance Technologies LLC (3.15%), Stonepine Capital Management LLC (2.83%), BlackRock Inc. (1.88%), Silverarc Capital Management LLC (1.55%) and Essex Investment Management Co. LLC (0.97%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes and Vijay Shreedhar.
View institutional ownership trends for Adamas Pharmaceuticals
.

Which major investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Deltec Asset Management LLC, Essex Investment Management Co. LLC, Squarepoint Ops LLC, Engineers Gate Manager LP, Fisher Asset Management LLC, Baker BROS. Advisors LP, and Northern Trust Corp. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, and Vijay Shreedhar.
View insider buying and selling activity for Adamas Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Silverarc Capital Management LLC, Stonepine Capital Management LLC, Renaissance Technologies LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., and BlackRock Inc..
View insider buying and selling activity for Adamas Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $4.74.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals has a market capitalization of $144.89 million and generates $54.64 million in revenue each year. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

Adamas Pharmaceuticals employs 136 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

Where are Adamas Pharmaceuticals' headquarters?

Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.